The differences of Matrix Metalloproteinases (MMP-9 and MMP-13) in chronic inflammatory rheumatic diseases

Abstract

"Objectives: Primary Sjogren's Syndrome (pSS), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are systemic, autoimmune, and chronic inflammatory rheumatic diseases that collagenases and gelatinases are effective and valuable in the pathophysiology of these diseases. The aim of this study is to compare the levels of MMP-9 (gelatinase-B) and MMP-13 (collagenase-3) in pSS to PsA, RA and healthy controls. Methods: Serum samples of patients with a diagnosis of Primer Sjögren's Syndrome (n=20), rheumatoid arthritis (n=20), psoriatic arthritis (n=19) and healthy control group (n=15) were analyzed by ELISA method for MMP-13 and MMP-9 levels. Results: There was no significant difference between the groups in terms of MMP-9 and MMP-13 levels. In the pSS group, MMP-9 was negatively correlated with MPP-13 (r:-0.568, p:0.09) but these parameters were not correlated with activity biomarkers and scores of disease activity index. In patients with pSS, the MMP-13 levels tended to be higher than the PsA patients and lower than RA patients but there was no significant difference between the 3 groups in terms of MMP-9 and MMP-13 levels. Conclusion: MMPs, in distinguishing health and disease conditions have various roles and they drive important biological mechanisms. Taking into account as a biomarker different body fluids need to be compared. In our study, the differences of serum samples between the pSS group and the positive control groups were not statistically significant. "